232 related articles for article (PubMed ID: 35772589)
1. Cholesterol crystals and atherosclerotic plaque instability: Therapeutic potential of Eicosapentaenoic acid.
John Chapman M; Preston Mason R
Pharmacol Ther; 2022 Dec; 240():108237. PubMed ID: 35772589
[TBL] [Abstract][Full Text] [Related]
2. Reducing residual cardiovascular risk in Europe: Therapeutic implications of European medicines agency approval of icosapent ethyl/eicosapentaenoic acid.
Chapman MJ; Zamorano JL; Parhofer KG
Pharmacol Ther; 2022 Sep; 237():108172. PubMed ID: 35304222
[TBL] [Abstract][Full Text] [Related]
3. Role of Omega-3 Fatty Acids in Cardiovascular Disease: the Debate Continues.
Sherratt SCR; Libby P; Budoff MJ; Bhatt DL; Mason RP
Curr Atheroscler Rep; 2023 Jan; 25(1):1-17. PubMed ID: 36580204
[TBL] [Abstract][Full Text] [Related]
4. Effect of Eicosapentaenoic Acid/Docosahexaenoic Acid on Coronary High-Intensity Plaques Detected Using Noncontrast T1-weighted Imaging: The AQUAMARINE EPA/DHA Randomized Study.
Nakao K; Noguchi T; Miura H; Asaumi Y; Morita Y; Takeuchi S; Matama H; Sawada K; Doi T; Hosoda H; Nakashima T; Honda S; Fujino M; Yoneda S; Kawakami S; Nagai T; Nishihira K; Kanaya T; Otsuka F; Nakanishi M; Kataoka Y; Tahara Y; Goto Y; Kusano K; Yamamoto H; Omae K; Ogawa H; Yasuda S
J Atheroscler Thromb; 2024 Feb; 31(2):122-134. PubMed ID: 37704431
[TBL] [Abstract][Full Text] [Related]
5. Effect of eicosapentaenoic acid/docosahexaenoic acid on coronary high-intensity plaques detected with non-contrast T1-weighted imaging (the AQUAMARINE EPA/DHA study): study protocol for a randomized controlled trial.
Nakao K; Noguchi T; Asaumi Y; Morita Y; Kanaya T; Fujino M; Hosoda H; Yoneda S; Kawakami S; Nagai T; Nishihira K; Nakashima T; Kumasaka R; Arakawa T; Otsuka F; Nakanishi M; Kataoka Y; Tahara Y; Goto Y; Yamamoto H; Hamasaki T; Yasuda S
Trials; 2018 Jan; 19(1):12. PubMed ID: 29310688
[TBL] [Abstract][Full Text] [Related]
6. Biologic plausibility, cellular effects, and molecular mechanisms of eicosapentaenoic acid (EPA) in atherosclerosis.
Borow KM; Nelson JR; Mason RP
Atherosclerosis; 2015 Sep; 242(1):357-66. PubMed ID: 26253795
[TBL] [Abstract][Full Text] [Related]
7. Eicosapentaenoic acid reduces membrane fluidity, inhibits cholesterol domain formation, and normalizes bilayer width in atherosclerotic-like model membranes.
Mason RP; Jacob RF; Shrivastava S; Sherratt SCR; Chattopadhyay A
Biochim Biophys Acta; 2016 Dec; 1858(12):3131-3140. PubMed ID: 27718370
[TBL] [Abstract][Full Text] [Related]
8. Eicosapentaenoic acid (EPA) has optimal chain length and degree of unsaturation to inhibit oxidation of small dense LDL and membrane cholesterol domains as compared to related fatty acids in vitro.
Sherratt SCR; Juliano RA; Mason RP
Biochim Biophys Acta Biomembr; 2020 Jul; 1862(7):183254. PubMed ID: 32135144
[TBL] [Abstract][Full Text] [Related]
9. Preferential Incorporation of Administered Eicosapentaenoic Acid Into Thin-Cap Atherosclerotic Plaques.
Sato T; Horikawa M; Takei S; Yamazaki F; Ito TK; Kondo T; Sakurai T; Kahyo T; Ikegami K; Sato S; Sato R; Jinno Y; Kawano H; Naoe S; Arita M; Kashiwagi Y; Setou M
Arterioscler Thromb Vasc Biol; 2019 Sep; 39(9):1802-1816. PubMed ID: 31366219
[TBL] [Abstract][Full Text] [Related]
10. A biological rationale for the disparate effects of omega-3 fatty acids on cardiovascular disease outcomes.
Sherratt SCR; Libby P; Bhatt DL; Mason RP
Prostaglandins Leukot Essent Fatty Acids; 2022 Jul; 182():102450. PubMed ID: 35690002
[TBL] [Abstract][Full Text] [Related]
11. Potential benefits of eicosapentaenoic acid on atherosclerotic plaques.
Nelson JR; Wani O; May HT; Budoff M
Vascul Pharmacol; 2017 Apr; 91():1-9. PubMed ID: 28263852
[TBL] [Abstract][Full Text] [Related]
12. Can pleiotropic effects of eicosapentaenoic acid (EPA) impact residual cardiovascular risk?
Nelson JR; True WS; Le V; Mason RP
Postgrad Med; 2017 Nov; 129(8):822-827. PubMed ID: 28974128
[TBL] [Abstract][Full Text] [Related]
13. Impact of the eicosapentaenoic acid to arachidonic acid ratio on plaque characteristics in statin-treated patients with coronary artery disease.
Asakura K; Minami Y; Nagata T; Katamine M; Katsura A; Hashimoto T; Kinoshita D; Ako J
J Clin Lipidol; 2023; 17(1):189-196. PubMed ID: 36517412
[TBL] [Abstract][Full Text] [Related]
14. Eicosapentaenoic acid (EPA) from highly concentrated n-3 fatty acid ethyl esters is incorporated into advanced atherosclerotic plaques and higher plaque EPA is associated with decreased plaque inflammation and increased stability.
Cawood AL; Ding R; Napper FL; Young RH; Williams JA; Ward MJ; Gudmundsen O; Vige R; Payne SP; Ye S; Shearman CP; Gallagher PJ; Grimble RF; Calder PC
Atherosclerosis; 2010 Sep; 212(1):252-9. PubMed ID: 20542512
[TBL] [Abstract][Full Text] [Related]
15. Effect of Omega-3 Fatty Acids on Coronary Plaque Morphology - A Serial Computed Tomography Angiography Study.
Motoyama S; Nagahara Y; Sarai M; Kawai H; Miyajima K; Sato Y; Matsumoto R; Takahashi H; Naruse H; Ishii J; Ozaki Y; Izawa H
Circ J; 2022 Apr; 86(5):831-842. PubMed ID: 34776470
[TBL] [Abstract][Full Text] [Related]
16. Lipid effects of switching from prescription EPA+DHA (omega-3-acid ethyl esters) to prescription EPA only (icosapent ethyl) in dyslipidemic patients.
Crandell JR; Tartaglia C; Tartaglia J
Postgrad Med; 2016 Nov; 128(8):859-864. PubMed ID: 27684412
[TBL] [Abstract][Full Text] [Related]
17. Emerging Mechanisms of Cardiovascular Protection for the Omega-3 Fatty Acid Eicosapentaenoic Acid.
Mason RP; Libby P; Bhatt DL
Arterioscler Thromb Vasc Biol; 2020 May; 40(5):1135-1147. PubMed ID: 32212849
[TBL] [Abstract][Full Text] [Related]
18. New Insights into Mechanisms of Action for Omega-3 Fatty Acids in Atherothrombotic Cardiovascular Disease.
Preston Mason R
Curr Atheroscler Rep; 2019 Jan; 21(1):2. PubMed ID: 30637567
[TBL] [Abstract][Full Text] [Related]
19. Effects of Fatty Acid Therapy in Addition to Strong Statin on Coronary Plaques in Acute Coronary Syndrome: An Optical Coherence Tomography Study.
Kita Y; Watanabe M; Kamon D; Ueda T; Soeda T; Okayama S; Ishigami K; Kawata H; Horii M; Inoue F; Doi N; Okura H; Uemura S; Saito Y
J Am Heart Assoc; 2020 Aug; 9(16):e015593. PubMed ID: 32805184
[TBL] [Abstract][Full Text] [Related]
20. Do patients benefit from omega-3 fatty acids?
Sherratt SCR; Mason RP; Libby P; Steg PG; Bhatt DL
Cardiovasc Res; 2024 Feb; 119(18):2884-2901. PubMed ID: 38252923
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
